Ask AI
ProCE Banner Activity

SPOTLIGHT: Phase III Study of First-line Zolbetuximab + mFOLFOX6 for Advanced CLDN18.2+/HER2- Gastric/Gastroesophageal Junction Adenocarcinoma

Conference Coverage
Slideset

Addition of zolbetuximab to mFOLFOX6 improved PFS and OS compared with mFOLFOX alone for previously untreated patients with advanced CLDN18.2+/HER2- gastric/gastroesophageal junction adenocarcinoma.

Released: January 25, 2023

Expiration: January 24, 2024

Review Activity

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

This activity is supported by educational grants from

Bristol Myers Squibb

Incyte Corporation

Merck Sharp & Dohme Corp.

Seagen Inc.